ITMI960311A0 - - Google Patents

Info

Publication number
ITMI960311A0
ITMI960311A0 ITMI960311A ITMI960311A ITMI960311A0 IT MI960311 A0 ITMI960311 A0 IT MI960311A0 IT MI960311 A ITMI960311 A IT MI960311A IT MI960311 A ITMI960311 A IT MI960311A IT MI960311 A0 ITMI960311 A0 IT MI960311A0
Authority
IT
Italy
Application number
ITMI960311A
Other languages
Italian (it)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI960311A0 publication Critical patent/ITMI960311A0/it
Priority to IT96MI000311A priority Critical patent/IT1282650B1/it
Priority to US08/799,313 priority patent/US5780057A/en
Priority to AT03078109T priority patent/ATE530173T1/de
Priority to DE69728710T priority patent/DE69728710T2/de
Priority to ES03078109T priority patent/ES2376199T3/es
Priority to DK97102567T priority patent/DK0795324T3/da
Priority to PT97102567T priority patent/PT795324E/pt
Priority to EP97102567A priority patent/EP0795324B1/en
Priority to NZ314265A priority patent/NZ314265A/en
Priority to AU14776/97A priority patent/AU719170B2/en
Priority to ES97102567T priority patent/ES2219709T3/es
Priority to EP03078109A priority patent/EP1382331B1/en
Priority to AT97102567T priority patent/ATE264670T1/de
Priority to JP03491897A priority patent/JP3251190B2/ja
Priority to CA002197941A priority patent/CA2197941C/en
Publication of ITMI960311A1 publication Critical patent/ITMI960311A1/it
Application granted granted Critical
Publication of IT1282650B1 publication Critical patent/IT1282650B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
IT96MI000311A 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici IT1282650B1 (it)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US08/799,313 US5780057A (en) 1996-02-19 1997-02-14 Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
NZ314265A NZ314265A (en) 1996-02-19 1997-02-18 Multilayered compressed tablet for selective release of medicaments at controlled rates having one layer that increases at least 50% by volume on contact with gastric juices
AU14776/97A AU719170B2 (en) 1996-02-19 1997-02-18 Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
ES03078109T ES2376199T3 (es) 1996-02-19 1997-02-18 Un comprimido farmacéutico caracterizado por mostrar un incremento de volumen cuando entra en contacto con fluidos biológicos.
DK97102567T DK0795324T3 (da) 1996-02-19 1997-02-18 En farmaceutisk tablet kendetegnet ved, at den udviser stor volumenforögelse, når den kommer i kontakt med biologiske væsker
PT97102567T PT795324E (pt) 1996-02-19 1997-02-18 Comprimido farmaceutico caracterizado por apresentar um elevado aumento volumerico quando colocado em contacto com fluidos biologicos
EP97102567A EP0795324B1 (en) 1996-02-19 1997-02-18 A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
AT03078109T ATE530173T1 (de) 1996-02-19 1997-02-18 Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
DE69728710T DE69728710T2 (de) 1996-02-19 1997-02-18 Eine pharmazeutische Tablette charakterisiert durch hohen Volumenzuwachs bei Kontakt mit biologischen Flüssigkeiten
ES97102567T ES2219709T3 (es) 1996-02-19 1997-02-18 Un comprimido farmaceutico caracterizado porque presenta un gran aumento de volumen cuando entra en contacto con fluidos biologicos.
EP03078109A EP1382331B1 (en) 1996-02-19 1997-02-18 A pharmaceutical tablet characterized by showing a high volume increase when coming into contact with biological fluids
AT97102567T ATE264670T1 (de) 1996-02-19 1997-02-18 Eine pharmazeutische tablette charakterisiert durch hohen volumenzuwachs bei kontakt mit biologischen flüssigkeiten
JP03491897A JP3251190B2 (ja) 1996-02-19 1997-02-19 体液と接触することにより容積が高度に増加する薬学的圧縮錠剤
CA002197941A CA2197941C (en) 1996-02-19 1997-02-19 A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Publications (3)

Publication Number Publication Date
ITMI960311A0 true ITMI960311A0 (h) 1996-02-19
ITMI960311A1 ITMI960311A1 (it) 1997-08-19
IT1282650B1 IT1282650B1 (it) 1998-03-31

Family

ID=11373320

Family Applications (1)

Application Number Title Priority Date Filing Date
IT96MI000311A IT1282650B1 (it) 1996-02-19 1996-02-19 Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici

Country Status (12)

Country Link
US (1) US5780057A (h)
EP (2) EP1382331B1 (h)
JP (1) JP3251190B2 (h)
AT (2) ATE530173T1 (h)
AU (1) AU719170B2 (h)
CA (1) CA2197941C (h)
DE (1) DE69728710T2 (h)
DK (1) DK0795324T3 (h)
ES (2) ES2219709T3 (h)
IT (1) IT1282650B1 (h)
NZ (1) NZ314265A (h)
PT (1) PT795324E (h)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US5804165A (en) * 1996-07-24 1998-09-08 Arnold; Michael J. Antiplaque oral composition
DE19640062B4 (de) * 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
IN186245B (h) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
GB9724186D0 (en) 1997-11-14 1998-01-14 British Tech Group Low temperature coatings
BR9814367A (pt) * 1997-12-22 2000-10-17 Schering Corp Formas de dosagens de ribavirina sólida administrável oralmente e processo para produzì-las
TR200003600T2 (tr) * 1998-06-05 2001-04-20 Warner-Lambert Company ACE inhibitörleri içeren bileşimlerin magnezyum oksit kullanılarak sabitlenmesi
CA2340130A1 (en) * 1998-09-25 2000-04-06 Suggy S. Chrai Liquid pharmaceutical for oral delivery
JP2002531491A (ja) 1998-12-11 2002-09-24 ノストラム・ファーマスーティカルズ・インコーポレイテッド ヒドロコロイドおよびセルロースエーテルを含む持続放出性錠剤
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
FR2797185B1 (fr) * 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EA200300046A1 (ru) * 2000-06-23 2003-10-30 Тева Фармасьютикал Индастриес Лтд. Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6881420B2 (en) * 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
BR0115585A (pt) 2000-11-28 2005-12-13 Fmc Corp Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento
WO2002045695A2 (en) * 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
KR100685945B1 (ko) 2000-12-29 2007-02-23 엘지.필립스 엘시디 주식회사 액정표시장치 및 그 제조방법
US8268333B2 (en) * 2001-04-24 2012-09-18 Lintec Corporation Orally administered agent and an orally administered agent/supporting substrate complex
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
IL159812A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core
IL159813A0 (en) * 2001-07-12 2004-06-20 Teva Pharma Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003042136A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. Process for the production of l-dopa ethyl ester
US6696600B2 (en) 2001-11-13 2004-02-24 Teva Pharmaceutical Industries, Ltd. L-DOPA ethyl ester salts and uses thereof
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
AU2002229678B2 (en) * 2001-12-21 2006-09-28 Biopartners Gmbh Ribavirin granulate for producing coated tablets
KR20030056474A (ko) * 2001-12-28 2003-07-04 한국유나이티드제약 주식회사 카르비도파/레보도파 서방정의 조성물과 그의 제조방법
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2002302890A1 (en) * 2002-02-04 2003-12-02 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
US7008979B2 (en) * 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
EP2422772A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
CN1731987A (zh) * 2002-10-31 2006-02-08 阿尔扎公司 提供液体制剂上升式释放的剂型
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US20050013863A1 (en) 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
EP1701725B1 (en) * 2003-12-16 2013-07-31 Relevare Aust. Pty Ltd Compositions comprising flupirtine and an opioid for use in the treatment of neuropathic pain
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
JPWO2005084703A1 (ja) * 2004-03-09 2007-11-29 株式会社Ｎｒｌファーマ 徐放性の口腔用組成物
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
EP1809259B1 (en) * 2004-10-15 2014-12-03 Supernus Pharmaceuticals, Inc. Less abusable pharmaceutical preparations
WO2006055928A2 (en) * 2004-11-19 2006-05-26 Smithkline Beecham Corporation Pharmaceutical product
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060159753A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Matrix type sustained-release preparation containing basic drug or salt thereof
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
RS20070512A (sr) * 2005-06-29 2009-01-22 Panacea Biotec Ltd., Farmaceutske kompozicije sa zadržanim otpuštanjem i postupci za njihovo dobijanje
CA2616416A1 (en) * 2005-09-09 2007-05-03 Labopharm, Inc. Trazodone composition for once a day adminisitiation
CA2616204C (en) * 2005-09-09 2015-12-01 Labopharm Inc. Sustained drug release composition
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
US8187633B2 (en) 2005-11-03 2012-05-29 Sun Pharma Advanced Research Company Limited Controlled release coated tablets having prolonged gastric retention
US20070178149A1 (en) * 2005-11-07 2007-08-02 Moshe Flashner-Barak Levodopa compositions
US7674396B2 (en) * 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
KR100752417B1 (ko) * 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
AU2007247851A1 (en) * 2006-05-03 2007-11-15 Relevare Aust. Pty Ltd Methods and composition for treatment of inflammatory pain
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
PL2484346T3 (pl) 2006-06-19 2017-07-31 Alpharma Pharmaceuticals Llc Kompozycje farmaceutyczne
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008025532A1 (en) 2006-08-30 2008-03-06 Jagotec Ag Controlled release solid oral dosage formulations comprising nisoldipine
WO2008039193A2 (en) * 2006-09-26 2008-04-03 Plensat, Llc Method and system for treatment of eating disorders
BRPI0622039B1 (pt) * 2006-09-26 2020-11-10 Plensat, Llc dispositivos gástricos ingeríveis de qualidade alimentícia
CA2664641A1 (en) * 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
EP1935411A1 (en) 2006-12-15 2008-06-25 Campina Nederland Holding B.V. Slow release excipient and its use
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
JPWO2008084698A1 (ja) 2006-12-28 2010-04-30 アステラス製薬株式会社 タクロリムス徐放性医薬組成物
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CN102123702A (zh) * 2008-06-16 2011-07-13 阿庇安实验室有限责任公司 制备恒定(零级)释放活性剂的释放体系的组合物和方法
CA2733787C (en) 2008-08-15 2016-09-06 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
EA201170529A1 (ru) 2008-10-08 2012-01-30 Биоплюс Лайф Саенсис Пвт. Лтд. Система доставки лекарственного препарата с замедленным высвобождением
US20100112054A1 (en) * 2008-10-23 2010-05-06 Appian Labs, Llc Tablets and discs with compartments with two or more drugs for release at certain intervals and with specific rates
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
EP2210585A1 (en) 2009-01-16 2010-07-28 Exelgyn SPRM pharmaceutical compositions methods of treatment using them
US20100249423A1 (en) * 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
WO2011078993A1 (en) 2009-12-21 2011-06-30 Aptapharma, Inc. Functionally-coated multilayer tablets
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20130143867A1 (en) * 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2806861A1 (en) 2012-01-23 2014-12-03 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CA2949372C (en) 2014-06-02 2023-08-22 Teva Pharmaceutical Industries Ltd. Expandable gastroretentive dosage form
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
US9617230B2 (en) 2014-12-22 2017-04-11 Farmington Pharma Development Creatine prodrugs, compositions and methods of use thereof
US10363288B2 (en) 2015-01-14 2019-07-30 National Jewish Health Insulin mimotopes and methods of using the same
IL283258B2 (en) * 2015-02-09 2023-11-01 Entera Bio Ltd A preparation for the treatment of hypothyroidism
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
CA3018727C (en) 2016-03-24 2024-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmune disease
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR20230088854A (ko) 2016-08-17 2023-06-20 엔테라 바이오 리미티드 활성 물질의 경구 투여용 제형
EP3547974B1 (en) 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Gastric residence system
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
AR118403A1 (es) 2017-12-01 2021-10-06 Ultragenyx Pharmaceutical Inc Profármacos de creatina, composiciones y métodos de uso de estos
WO2019111132A1 (en) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Long acting gastric residence system
AU2018388577B2 (en) 2017-12-18 2024-06-06 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
WO2019126214A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release
CA3085941A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN115844894B (zh) * 2018-05-15 2024-08-06 江苏豪森药业集团有限公司 包含第三代小分子egfr抑制剂的药物组合物及其制备方法
CN110214860A (zh) * 2019-07-10 2019-09-10 聂刘明 一种宠物饲料及其制备工艺
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
CA3196650A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12409163B2 (en) 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
CA3226223A1 (en) * 2021-07-30 2023-02-02 Jacob Pade Ramsoe Jacobsen 5-hydroxytryptophan gastroretentive dosage forms
WO2023064598A1 (en) 2021-10-14 2023-04-20 Evecxia Therapeutics, Inc. A method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
WO2023214018A1 (en) 2022-05-06 2023-11-09 Galenix Innovations Gastro-retentive swellable sustained release composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4839171A (en) * 1984-11-30 1989-06-13 Techmix, Inc. Composition for treating impaired lactation
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
JPH0747534B2 (ja) * 1986-06-02 1995-05-24 ロ−ラ−ジヤパン株式会社 錠 剤
US4869908A (en) * 1987-01-09 1989-09-26 K.V. Pharmaceutical Co. Fibre formulations
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1256393B (it) * 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time

Also Published As

Publication number Publication date
ES2376199T8 (es) 2012-04-04
JP3251190B2 (ja) 2002-01-28
DK0795324T3 (da) 2004-08-16
EP0795324B1 (en) 2004-04-21
EP1382331B1 (en) 2011-10-26
CA2197941A1 (en) 1997-08-20
ES2219709T3 (es) 2004-12-01
CA2197941C (en) 2001-12-04
IT1282650B1 (it) 1998-03-31
ES2376199T3 (es) 2012-03-09
JPH09316005A (ja) 1997-12-09
EP0795324A3 (en) 1998-11-04
EP1382331A1 (en) 2004-01-21
NZ314265A (en) 1997-07-27
AU719170B2 (en) 2000-05-04
AU1477697A (en) 1997-08-28
DE69728710T2 (de) 2005-04-07
EP0795324A2 (en) 1997-09-17
ATE264670T1 (de) 2004-05-15
ITMI960311A1 (it) 1997-08-19
DE69728710D1 (de) 2004-05-27
ATE530173T1 (de) 2011-11-15
PT795324E (pt) 2004-09-30
US5780057A (en) 1998-07-14

Similar Documents

Publication Publication Date Title
AR026661A2 (h)
BRPI9713914B8 (h)
ITAN960020A0 (h)
ITMI960438A0 (h)
BR7600721U (h)
BR7601346U (h)
BR9603859A (h)
CN3039213S (h)
CN3040024S (h)
CN3040367S (h)
CN3040543S (h)
CN3040550S (h)
CN3040805S (h)
CN3041115S (h)
CN3041207S (h)
CN3041374S (h)
CN3041383S (h)
CN3042193S (h)
CN3042289S (h)
CN3042424S (h)
CN3042589S (h)
CN3043305S (h)
CN3043413S (h)
CN3043414S (h)
CN3043415S (h)

Legal Events

Date Code Title Description
0001 Granted